BioNexus Gene Lab Corp. (BGLC)

BioNexus Gene Lab Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Revenue	5.31	7.42	9.51	9.77	10.93
Revenue Growth (YoY)	-42.69%	-21.93%	-2.66%	-10.60%	-
Cost of Revenue	4.57	6.34	8.22	8.44	9.67
Gross Profit	0.74	1.09	1.29	1.33	1.26
Selling, General & Admin	2.72	3.27	3.86	3.04	1.73
Research & Development	0.05	0.05	0.05	0.05	-
Other Operating Expenses	0.46	1.16	1.02	1.31	-
Total Operating Expenses	3.23	4.48	4.94	4.41	1.73
Operating Income	-2.89	-2.97	-1.57	-2.59	-0.29
Interest Income	0.09	0.11	0.22	0.13	-
Interest Expense	-0.02	-0.02	-0.02	-0.01	-0.01
Other Non-Operating Income (Expense)	0.21	0.33	1.86	0.36	0.18
Total Non-Operating Income (Expense)	0.29	0.41	2.05	0.47	0.17
Pretax Income	-2.9	-2.98	-1.59	-2.61	-0.3
Provision for Income Taxes	-	-	0	0.02	0.05
Net Income	-2.9	-2.98	-1.6	-2.63	-0.36
Net Income to Common	-2.9	-2.98	-1.6	-2.63	-0.36
Shares Outstanding (Basic)	2	2	2	1	1
Shares Outstanding (Diluted)	2	2	2	1	1
Shares Change (YoY)	12.44%	4.20%	23.66%	-	-
EPS (Basic)	-1.49	-1.61	-0.90	-0.17	-0.46
EPS (Diluted)	-1.49	-1.61	-0.90	-0.17	-0.46
Shares Outstanding	2.42	2.42	1.8	1.77	1.45
Free Cash Flow	-1.19	-1.88	-2.32	-1.97	0.5
Free Cash Flow Per Share	-0.59	-1.01	-1.30	-1.37	0.35
Gross Margin	13.95%	14.62%	13.56%	13.61%	11.52%
Operating Margin	-54.36%	-39.93%	-16.55%	-26.54%	-2.66%
Profit Margin	-54.70%	-40.20%	-16.81%	-26.91%	-3.26%
FCF Margin	-22.41%	-25.26%	-24.40%	-20.18%	4.55%
EBITDA	-2.71	-2.8	-1.42	-2.49	-0.19
EBITDA Margin	-51.12%	-37.67%	-14.94%	-25.43%	-1.70%
EBIT	-2.89	-2.97	-1.57	-2.59	-0.29
EBIT Margin	-54.36%	-39.93%	-16.55%	-26.54%	-2.66%
Effective Tax Rate	-	0.00%	-0.22%	-0.83%	-17.23%

Updated May 15, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q